A Phase I, Open-Label, Multi-Center Study of CKD-581 in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 03 Aug 2018
Price : $35 *
At a glance
- Drugs CKD 581 (Primary) ; Bortezomib; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Chong Kun Dang
- 25 Jul 2018 Planned End Date changed from 1 Aug 2019 to 1 Jun 2021.
- 25 Jul 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Jun 2019.
- 17 Feb 2017 New trial record